Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Kimmtrak® (tebentafusp-tebn) – New orphan drug approval
January 26, 2022 - Immunocore announced the FDA approval of Kimmtrak (tebentafusp-tebn), for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
